$44.65
-0.23-0.51%
Last update: Aug 27, 12:53 PM
Supernus Pharmaceuticals Inc
SUPNNASDAQ
Supernus Pharmaceuticals Earnings & Forecasts
Supernus Pharmaceuticals (SUPN) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Supernus Pharmaceuticals Guidance
Supernus Pharmaceuticals (SUPN) last issued guidance on August 3, 2026 for fiscal year 2026. The company guided revenue in the range of $860M - $890M for the period.
Compared to prior guidance, Supernus Pharmaceuticals raised its revenue forecast from a prior range of $840M - $870M.
Supernus Pharmaceuticals has issued 16 guidance updates between November 8, 2022 and August 3, 2026. During this period, the company raised its outlook 6 times and lowered it 2 times, providing investors with insight into management's evolving expectations.
Recent Earnings Results
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.42 | $0.25 | $0.22 | $0.62 |
| Actual | $0.53 | $-0.04 | $-0.07 | $-0.80 |
| Surprise | +26.2% | -116.0% | -131.8% | -229.0% |
| Revenue | ||||
| Estimate | $205.5M | $192.0M | $195.8M | $181.0M |
| Actual | $219.1M | $207.7M | $211.6M | $192.1M |
| Surprise | +6.59% | +8.17% | +8.07% | +6.16% |
Analyst Estimates — Forward PeriodsSource: Wall Street consensus
| Metric | Q3 '26E | Q4 '26E | Q1 '27E |
|---|---|---|---|
| Earnings Per Share (Non-GAAP) | |||
| Consensus | $0.62 | $1.02 | $0.39 |
| Revenue | |||
| Consensus | $221.3M | $238.1M | — |
